Activation of EGFR leads to downstream activation of MAPKs, however, the efficiency of the EGFR inhibitor erlotinib in clinical trials of CCA is limited according to a Multicenter Phase II clinical trial testing [165,195]. The gene discussed is EGFR; the disease is cholangiocarcinoma.